Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts by Chaoming Zhou et al.
RESEARCH ARTICLE Open Access
Anti-fibrotic action of pirfenidone in
Dupuytren’s disease-derived fibroblasts
Chaoming Zhou1, Fang Liu1, Phillip H. Gallo1, Mark E. Baratz2, Sandeep Kathju3,4 and Latha Satish3,4*
Abstract
Background: Dupuytren’s disease (DD) is a complex fibro-proliferative disorder of the hand that is often
progressive and eventually can cause contractures of the affected fingers. Transforming growth factor beta (TGF-β1)
has been implicated as a key stimulator of myofibroblast activity and fascial contraction in DD. Pirfenidone (PFD) is
an active small molecule shown to inhibit TGF-β1-mediated action in other fibrotic disorders. This study investigates
the efficacy of PFD in vitro in inhibiting TGF-β1-mediated cellular functions leading to Dupuytren’s fibrosis.
Methods: Fibroblasts harvested from (DD) and carpal tunnel (CT)- tissues were treated with or without TGF-β1 and/
or PFD and were subjected to cell migration, cell proliferation and cell contraction assays. ELISA; western blots and
real time RT-PCR assays were performed to determine the levels of fibronectin; p-Smad2/Smad3; alpha-smooth
muscle actin (α-SMA), α2 chain of type I collagen and α1 chain of type III collagen respectively.
Results: Our results show that PFD effectively inhibits TGF-β1-induced cell migration, proliferation and cell
contractile properties of both CT- and DD-derived fibroblasts. TGF-β1−induced α-SMA mRNA and protein levels
were inhibited at the higher concentration of PFD (800 μg/ml). Interestingly, TGF-β1 induction of type I and type III
collagens and fibronectin was inhibited by PFD in both CT- and DD- derived fibroblasts, but the effect was more
prominent in DD cells. PFD down-regulated TGF-β1-induced phosphorylation of Smad2/Smad3, a key factor in the
TGF-β1 signaling pathway.
Conclusion: Taken together these results suggest the PFD can potentially prevent TGF-β1−induced fibroblast to
myofibroblast transformation and inhibit ECM production mainly Type I- and Type III- collagen and fibronectin in
DD-derived fibroblasts. Further in-vivo studies with PFD may lead to a novel therapeutic application in preventing
the progression or recurrence of Dupuytren’s disease.
Keywords: Dupuytren’s contracture, Palmar fascia fibrosis, Carpal tunnel, Collagen, Alpha-SMA, Smad2/Smad3, Cell
migration, Cell contraction
Background
Dupuytren’s disease (DD) is a common fibroproliferative
disorder of the hand that is often progressive and even-
tually can cause contractures of the affected fingers [1].
DD is considered to be caused by a defect in the process
of wound healing or by an excessive or abnormal
response to wounding [2]. DD is a multifactorial and
complex disease, and has been reported to have an asso-
ciation with inherited genetic markers, alcohol and
tobacco use [3], and different systemic diseases such as
diabetes [4], and epilepsy [5]. The disease usually begins
with the formation of highly vascularized nodules and
over the years develops into collagenous rich cords.
Myofibroblasts that share characteristic features of both
fibroblasts and smooth muscle cells have been shown to
play a critical role in tissue contraction of DD [6, 7].
Acting along with this cell population are several growth
factors and cytokines that are implicated in the progres-
sion of the disease [2, 8].
Dupuytren’s disease commonly affects populations of
northern European descent, with the prevalence of DD
in the general population of Western countries ranging
from 0.6 to 31.6% [9]. The prevalence rate in the United
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States is reported to be >7% [10]. In the USA, disability
and treatments for DD account for significant losses to
the economy and substantial direct and indirect costs
[11]. At present there is no cure for DD. The corner-
stone of treatment has, historically, been surgical exci-
sion of involved palmar fascia release of diseased skin.
More recently percutaneous needle fasciotomy and
collagenase injections in the cords, is practiced as an
alternative to more invasive surgery [12, 13]. Recurrence
rates seem to be higher with the less invasive techniques
and these strategies do have their own unique complica-
tions [14, 15]. Recurrence of DD overall ranges from 8
to 66% depending on the severity and treatment of
disease [16], underscoring the importance of additional
research on the causes and factors related to recurrence.
Among all the growth factors that have been studied in
DD, transforming growth factor – β (TGF-β) is shown to
play a major role in the pathophysiology of DD [17, 18].
In fibroblasts derived from Dupuytren’s affected and
unaffected tissue, TGF-β can upregulate α-SMA and is
recognized to be the key inducer in differentiating a quies-
cent fibroblast to a contracting myofibroblast [18]. The
inhibition or reversion of the myofibroblast phenotype to
normal may mitigate disease progression and severity.
Previous studies from our laboratory have shown that
increasing cyclic AMP (cAMP) levels via forskolin (an
adenylate cyclase (AC) activator) has potential to inhibit
TGF-β-induced myofibroblast formation and accumula-
tion of ECM components in DD-derived fibroblasts [19].
Overproduction of cAMP that can provide a means to
blunt fibrosis has also been shown in cardiac and pulmon-
ary fibroblasts [20, 21]. Clinical data about the usage of
forskolin are not yet available as the risk-benefit ratio is
not fully evaluated [22].
In the present study, we have chosen to investigate the
action of pirfenidone (PFD; 5-methyl-1-phenyl-2(1H)-
pyridone) a small molecule well-documented for its anti-
fibrotic and anti-inflammatory properties in a variety of
pre-clinical and in vitro models in different organs,
including fibrosis of the lung [23], kidney [24], heart
[25], liver [26], and skin [27]. PFD has been shown to
inhibit both production and activity of TGF-β1, a cyto-
kine that stimulates collagen synthesis and inhibits its
degradation [28], and also to reduce the production of
other fibrogenesis mediators, such as fibronectin and
connective tissue growth factor (CTGF) [29, 30]. The
ability of PFD to combat the fibrosis seen in DD has not
previously been reported. PFD is an FDA approved drug
for the treatment of idiopathic pulmonary fibrosis in the
United States, and thus represents an attractive potential
therapy for Dupuytren’s disease.
In this study we examine the ability of PFD to modulate
TGF-β1-mediated actions on the DD fibroblast’s func-
tional properties, namely cell proliferation, cell migration
and cell contraction. In addition, we also examine the
effect of PFD on the canonical signaling pathway known
to mediate TGF-β1 effects in other fibrotic systems.
Methods
Cell culture
Primary cultures of fibroblasts were isolated from freshly
resected DD cord tissue and normal palmar fascia (CT
cells) as previously described [31]. DD cord and CT fascial
tissue samples were surgically resected at the Division of
Upper Extremity Surgery, Department of Orthopaedic
Surgery, Allegheny General Hospital, Pittsburgh, PA. All
subjects signed the written informed consent forms, and
the protocol was approved by the Allegheny-Singer Re-
search Institute’s Institutional Review Board (IRB protocol
no. RC-4040). The study protocol strictly conformed to
the ethical guidelines of the 1975 Declaration of Helsinki.
Cells are maintained in alpha-MEM medium (Invitrogen™,
ThermoFisher Scientific, Pittsburgh, PA) with 10% FBS
and Penicillin/Streptomycin antibiotics (Gibco®, Thermo-
Fisher Scientific) with 5% CO2. Cells used for all experi-
ments were within passages two to seven.
Cell viability/proliferation
CT- and DD-cord-derived fibroblasts (5 × 104) seeded on
a 24 well plate were grown overnight in alpha-MEM
medium containing 10% FBS. Following day, cells were
switched to alpha-MEM medium containing 0.1%
dialyzed FBS for 24 h followed by treatment with different
concentrations of PFD (0, 200, 400 and 800 μg/mL) with
or without 10 ng/ml TGF-β1 in low-serum medium for
additional 24 h. After the incubation period, cells were
photographed, and MTT assay was performed using the
CellTiter 96® Non-Radioactive Cell Proliferation Assay kit
obtained from Promega Corporation (Madison, WI) [31].
Cells were replaced with fresh growth medium and dye
solution and incubated at 37 °C for 2 h. After adding
solubilization/stop solution, cells were incubated for
another 1.5 h at 37 °C. Results were obtained using a plate
reader by measuring absorption at 570 nm of 100 μl ali-
quots placed into a Corning 96 well flat transparent plate.
Lactate Dehydrogenase (LDH) cytotoxicity assay
LDH is a cytosolic enzyme that is not normally discharged
outside of the cell, but is released into the cell culture
medium upon damage to the cellular membrane. Meas-
urement of extracellular LDH release into the culture
medium can be used to assay cellular toxicity. CT- and
DD-derived fibroblasts (5 × 104) were seeded in a 24 well
plate and were grown overnight in alpha-MEM medium
containing 10% FBS. Following day, cells were switched to
alpha-MEM medium containing 0.1% dialyzed FBS for
24 h followed by treatment with different concentrations
of PFD (0, 200, 400 and 800 μg/mL) in low-serum
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medium for an additional 24 h. After 24 h of exposure,
extracellular LDH activity was measured using the In
Vitro Toxicology Assay Kit, Lactate Dehydrogenase-based
(Sigma-Aldrich, St. Louis, MO) according to the manufac-
turer’s instructions. The absorbance of LDH release (from
medium) was separated and measured using a plate reader
at a wavelength 490 nm (primary) and 690 nm (back-
ground) by aliquoting 30 μL into a Corning 96 well flat
transparent plate. LDH activity was expressed as fold
change versus control samples after the background
subtraction.
Cell migration
Cell migration assays were done using the Oris™ Cell
Migration assay (Platypus Technologies, Fitchburg, WI)
which offers an alternative to the “scratch” test which
can vary between experiments and can disrupt extracel-
lular matrix which is vital for cell migration. In brief, this
procedure employs a stopper dissolvable biocompatible
gel (BCG) to create the cell-free gap in the center of a
well in a microplate. Cells seeded into each well are ini-
tially restricted from adhering to the center of each well
creating a “detection zone”. CT- and DD-cord derived
fibroblasts were stained with 3 μM CellTracker™ Red
CMTPX Dye (Molecular Probes™, ThermoFisher Scien-
tific) in alpha-MEM medium containing 10% FBS for
30 min. Cells (1 × 104) were seeded into the wells
containing Oris™ Cell Stoppers in Fibronectin Coated or
Non-Coated 96- well plate (Platypus Technologies,
Fitchburg, WI) and incubated overnight. Following day,
the cell stoppers were removed carefully using the Stop-
per tool leaving the internal controls. Cells were
quiesced in the medium containing 0.1% dialyzed FBS
for 24 h. Cells were treated with PFD (800 μg/mL) with
or without 10 ng/ml TGF-β1 in low-serum medium for
additional 24 h. The stoppers in the internal control well
were removed just before imaging. The cell migration
was assessed by a number of cells that enter the detec-
tion zone using NIH Image J 1.44p, available in the
public domain at http://imagej.nih.go/ij.
Stressed Fibroblast -Populated Collagen Lattice Assay
(sFPCL)
Cell contractility of the fibroblasts was tested using
FPCL assay as previously described with slight modifica-
tions [32]. In brief, collagen lattices were prepared by
mixing cell suspensions with a neutralized solution of
type I collagen matrix (four parts rat tail collagen, one
part neutralization solution; two parts 0.34 M NaOH: 3
parts 10X Waymouth media). Cells were exposed to
alpha-MEM medium containing 0.1% dialyzed FBS 24 h
prior to plating in 24-well plate. Each well in a 24-well
culture dish contained 1 × 105 of CT- and DD-derived
fibroblasts in 0.5 ml of the collagen mixture along with
or without PFD (800 μg/ml) and TGF-β1 (10 ng/ml).
Following FPCL polymerization (1 h, 37 °C), 0.5 ml of
alpha-MEM medium containing 2% FBS was added to
the top of each lattice and incubated overnight. After
24 h incubation, the attached FPCLs were then manually
released from the sides of the culture plates and digitally
scanned every 24 h after release until day 6. The area of
the lattices was quantified using Adobe Photoshop and
was plotted.
Quantitative Real-time RT-PCR (qRT-PCR)
Total RNA isolated (RNeasy Micro Kit, Qiagen Inc,
Valencia, CA) from CT- and DD-derived fibroblasts
treated and untreated with PFD (800 μg/ml) and TGF-β1
(10 ng/ml) was subjected to real-time RT-PCR to deter-
mine the mRNA expression levels for α-SMA (ACTA2),
type I collagen (COL1A2), and type III collagen (COL3A1).
Human GAPDH was used as an normal endogenous con-
trol. Real-time RT-PCR was performed using kits obtained
from Applied Biosystems (Applied Biosystems®, Thermo-
Fisher Scientific) that utilize FAM™Taqman®MGB probes
and a Taqman®Universal PCR Master Mix. 100 ng of total
RNA from samples were used for the reverse transcriptase
(RT) reaction along with random primers (100 ng) and
with M-MLV reverse transcriptase (Invitrogen). Taqman
probes for above-noted gene products were purchased
from Applied Biosystems. The remaining protocol param-
eters for subsequent real- time PCR was followed as
described previously19. Applied Biosystems transcript-
specific assays used were COL1A2 (ID- Hs01028971_ml),
COL3A1 (ID-Hs00943793), ACTA2 (ID-HS00426835_g1)
and GAPDH (ID-Hs99999905_m1). Using the compara-
tive critical cycle (Ct) method the expression levels of the
target genes were normalized to the GAPDH and the
relative abundance was calculated. Data were analyzed
using the 7900 HT SDS software version 2.2.2 provided by
Applied Biosystems.
Western blotting
CT- and DD-derived fibroblasts (2 × 105) were seeded in
six well plates with growth medium containing 10% FBS
overnight followed by exposing the cells in 0.1% dia-
lyzed FBS-containing medium for 24 h. Cells were
treated with 800 μg/ml PFD with or without 10 ng/ml
TGF-β1 in low-serum medium for an additional 24 h.
Following the treatment cells were washed with ice-cold
PBS once and then lysed in M-PER™ Mammalian Protein
Extraction Reagent (ThermoFisher Scientific) with pro-
teinase inhibitors (cOmplete ULTRA Tablets, Mini,
EDTA-free) and Phosphostop purchased from Roche
Diagnostics Corporation (Indianapolis, IN). Proteins were
resolved by SDS-PAGE, and standard Western blotting
procedure was applied. Primary antibodies used were:
mouse monoclonal anti-Actin α Smooth Muscle
Zhou et al. BMC Musculoskeletal Disorders  (2016) 17:469 Page 3 of 12
Antibody (predicted and observed molecular weight is
42 kDa 1:5000; Sigma-Aldrich, St. Louis, MO), mouse
monoclonal anti-GAPDH antibody, detects a band ap-
proximately at ~36 kDa and the predicted molecular
weight is 40.2 kDa (1:5000; Abcam, Cambridge, MA),
phosphor-Smad2 (Ser465/467)/Smad3(Ser423/425)(D27F4)
(1:1000) Rabbit mAb (1:1000) (Cell Signaling, Boston, MA).
The predicted molecular weight for pSMAD2 is 60KDa
and for pSMAD3 is 52KDa. The observed molecular
weights approximate the predicted molecular weights.
Membranes were washed and then incubated for an
hour in room temperature with IRDye 800CW Gt Anti-
Rabbit IgG (H + L) antibody and IRDye 680LT Anti-Mouse
IgG (H+ L) antibody (1:15,000) (Li-COR Bioscience,
Lincoln, NE). Infrared fluorescence was detected by the
Odyssey® Imaging System (Li-COR Bioscience). The
protein bands scanned were analyzed using NIH Image J
1.44p. The data obtained was normalized with GAPDH.
Enzyme- Linked Immunosorbent Assay (ELISA)
CT- and DD-derived fibroblasts (1 × 104) seeded in 96
well plates were grown in growth medium overnight,
and cells were changed to medium containing 0.1%
dialyzed FBS for 24 h. Cells were treated with 800 μg/mL
of PFD with or without 10 ng/ml TGF-β1 in low-serum
medium for another 24 h. Following the treatment, se-
creted proteins in the growth medium were collected in
the conditioned medium, which was centrifuged for
10 min to collect the supernatant. Fibronectin levels were
analyzed in the supernatants using Human Fibronectin
SimpleStep ELISA Kit from Abcam according to the man-
ufacturer’s instructions.
Results
Effect of PFD on the proliferative efficiency of CT- and
DD-derived fibroblasts
Various concentrations of PFD (0, 200, 400, 800 μg/ml)
were tested on CT- and DD-cord derived fibroblasts
with or without the stimulation of TGF-β1. A dose-
dependent effect on cell proliferative efficiency was seen
in both CT-and DD-cord derived fibroblasts (Fig. 1a and
b). A statistically significant inhibition of both basal and
TGF-β1 stimulated cell proliferation was observed at all
the different concentrations, and highest inhibition was
seen at 800 μg/ml. In order to confirm that the reduc-
tion of cell proliferative efficiency observed was not due
to cytotoxicity we performed LDH assay and determined
that there was no cytotoxic effect observed 24 h after
treating with different doses of PFD (Fig. 2). No change
in cellular morphology (data not shown) was observed,
confirming the non-toxic effect of PFD even at higher
concentrations on both CT- and DD-cord derived fibro-
blasts. To determine the functional significance of inhib-
ition of PFD on CT and DD-cord derived fibroblasts,
800 μg/ml of PFD was used for further experimentation.
PFD significantly inhibits basal and growth factor-induced
cell migration on both 2D and 3D surfaces
It is still unclear what role migration of cells plays in the
development of the diseased cord in DD disease,
although given the severity of contractures that can form
some migration of cells as well as cellular contraction
Fig. 1 Cell proliferative ability was diminished after the addition of Pirfenidone. (a) CT- and (b) DD-derived fibroblasts derived from four different
patient samples (N = 4/group) were exposed to varying concentrations of PFD (0, 200, 400, 800 μg/ml) and TGF-β1 (10 ng/ml). Cells were then
subjected to MTT assay to determine the effect of PFD on basal and TGF-β1-induced cell proliferation. Cell proliferation is displayed as absorbance
values of untreated CT-derived fibroblasts normalized to 1 and compared with other treatments. Data are shown as mean ± SEM of the averages
of triplicate reads for each culture derived from the four different patient samples both for CT- and DD-derived fibroblasts. Statistical analysis was
performed using one-way ANOVA. *p < 0.05; **p < 0.01
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seems likely. Our previous studies have shown that the
basal cell migratory potential of DD cells was much
higher than that of CT- derived fibroblasts (data not
shown). In the present study, we investigated the effect
of PFD (800 μg/ml) on basal and TGF-β1-induced cell
migration on fibronectin non-coated (2D) and coated
surfaces (3D). No significant cell migratory stimulus was
observed from the addition of TGF-β1 in both CT-and
DD-cord derived fibroblasts in both fibronectin non-
coated (Fig. 3a &b) and coated surface plates (Fig. 3c
&d). Interestingly, a significant inhibition of basal cell
migration was noted in both CT-and DD-cord derived
fibroblasts in both 2D and 3D assays when the cells were
treated with PFD. The addition of PFD to TGF-β1-stim-
ulated cells similarly reduced cell capacity to migrate.
PFD inhibition of basal- and TGF-β1- induced cell contraction
is evident in both CT- and DD-cord derived fibroblasts
TGF-β1 is a growth factor known to induce fibroblast
contraction, and it is known to play a critical role in the
development of Dupuytren’s disease. Indeed, the deform-
ing force of cellular contraction, on a tissue level, must
play a critical role in the development of the extreme
contractures that can develop. We determined that
TGF-β1 induced contraction of both CT-and DD-
derived fibroblasts, whereas addition of PFD abrogated
both basal- and TGF-β1-mediated- contraction (Fig. 4a,
b & c). Since α-SMA is the major protein involved in the
molecular generation of cellular contraction force, we
questioned if the increase in α-SMA levels engendered
by TGF-β1 can be reduced by the addition of PFD. We
found that PFD substantially inhibited TGF-β1- induced
α-SMA at both mRNA (Fig. 5a & b) and protein levels
(Fig. 5c & d) in both CT- and DD-derived fibroblasts.
PFD by itself did not have any significant effect on
α-SMA mRNA or protein levels in both cell types. These
results again strongly indicate that DD fibroblastic cells,
in a manner similar to normal fibroblasts, are responsive
to PFD action, highlighting the potential of the drug as a
candidate to inhibit myofibroblast formation in DD, in
turn likely reducing DD contractures.
PFD attenuates type I and type III collagen subunit mRNA
expression in both CT- and DD-derived fibroblasts
Since increased collagen accumulation is the hallmark
for fibrosis and the progression of Dupuytren’s disease
[33], our next goal was to investigate if PFD can inhibit
collagen accumulation. Interestingly, we found that both
basal expression and TGF-β1 induction of type I (α-2
chain; COL1A2) and type III collagen (α-1 chain;
COL3A1) mRNA levels were significantly inhibited in
both CT- and DD- derived fibroblasts by addition of
PFD (Fig. 6a – d). PFD appears to more greatly inhibit
collagen message in DD cells compared to CT cells.
These fingings reiterate PFD as an attractive candidate
to mitigate collagen accumulation (and therefore disease
phenotype) in DD.
PFD suppresses TGF-β1- induced fibronectin protein
levels
The palmar fascia fibrosis seen in DD is associated with
excessive deposition of extracellular matrix (ECM) com-
ponents including fibronectin [19]. DD tissues and cells
have been reported to show increased expression of
fibronectin type III extra-domain B (FN 1-ED-B) and
“oncofetal” fibronectin levels [34, 35] which prompted
us to determine if PFD can play a role in reducing fibro-
nectin levels. We found that PFD (800 μg/ml) decreased
TGF-β1- induced fibronectin protein levels in both CT-


















Fig. 2 Cell viability was not affected by the presence of Pirfenidone. CT- and DD-derived fibroblasts derived from three different patient samples
(N = 3/group) were incubated with different concentrations of PFD (0, 200, 400, 800 μg/ml), and the extracellular LDH release into the culture
medium was measured as described in Materials and Methods. Data are shown as mean ± SEM of the averages of triplicate reads for each culture
derived from the four different patient samples both for CT- and DD-derived fibroblasts. Ntx = no treatment (neither PFD nor TGF-β1 added
control). Statistical analysis was performed using one-way ANOVA. *p < 0.05; **p < 0.01
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PFD inhibits TGF-β1-induced phosphorylation of Smad2/
Smad3
Studies have shown that TGF-β1 is a potent modulator
of fibroblast and myofibroblast proliferation and differ-
entiation [7]. All key components of the TGF-β1/Smad
signaling cascade were noted to have increased expres-
sion patterns in DD, resulting in accelerated TGF-β1 sig-
naling [36]. We examined the phosphorylation of
Smad2/Smad3 protein as a measure for active canonical
TGF-β1 signaling. We detected an increase in protein
levels of phospho-Smad2/3 when stimulated with TGF-
β1 in both CT- and DD-derived fibroblasts. This increase
in expression was attenuated by the addition of PFD
(Fig. 8a & b).
Statistical analysis
Statistical analyses were performed by one way ANOVA
using GraphPad Prism version 7.0. Statistically signifi-
cant differences between paired experimental and con-
trol groups; and paired treatments between CT cells and
DD cells was performed using Dunnett’s and Sidak’s ana-
lyses. One sample T-test was used to compare the back-
ground between CT and DD cell population. A p value
<0.05 was considered significant.
Discussion
DD is a chronic, fibroproliferative disorder with high re-
currence rate after all available strategies for treatment.




Fig. 3 Pirfenidone suppressed basal and TGF-β1 induced cell migration. CT- and DD-derived fibroblasts derived from three different pateint samples
(N = 3/group) were maintained in low-serum medium for 24 h, then were left untreated (Ntx) or exposed to PFD (800 μg/ml) in the presence or absence
of TGF-β1 (10 ng/ml) to perform the 2D (a & b) and OrisTM 3D (c & d) cell migration assays. Shown here are representative images of three different
experiments from three different cultures (N = 3/group) of CT- and DD-derived fibroblasts done for 2D (a) and 3D (c) migration assays in triplicate.
NIH- image analysis was used to assess the number of cells that entered the detection zones after various treatments. Data are shown as mean ± SEM of
the averages of triplicate reads for each culture derived from the three different patient samples both for CT- and DD- derived fibroblasts. Statistical
analysis was performed using one-way ANOVA. *p< 0.05; **p< 0.01, ***p< 0.001
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trend to recurrence remains under investigation. Our
work has shown that not only fibroblasts from actively
diseased cords, but also fibroblasts from phenotypically
normal adjacent palmar fascia in DD have significantly
altered patterns of gene expression compared to control
cells from CT patients [37]. These nearby cells may
therefore represent a residual manifestation of proto-
disease after surgery, which may be stimulated by
cytokine mediators to progress to active, frank recur-
rence. An important such mediator, known to promote
the conversion of fibroblasts to an activated myofibro-
blast phenotype and known to play a role in DD, is
TGF-β1. Accordingly, therapies that can counteract
TGF-β1 may also prove useful in dealing with DD.
The link between elevated TGF-β1 and fibrosis is well




Fig. 4 Cellular contractile ability was diminished in the presence of Pirfenidone. CT- and DD-derived fibroblasts derived from four different patient
samples (N = 4/group) were left untreated (Ntx) or exposed to PFD (800 μg/ml) in the presence or absence of TGF-β1 (10 ng/ml) to perform the stressed
fibroblast populated collagen lattice (sFPCL) assay. Collagen lattices cultured for 24 h were detached from the surface of the well, and the digital images
of the floating lattices were captured at different time points (day 0- day 6). a Shown here are representative images of four independent experiments
performed in duplicate. b & c Data were obtained using Adobe Photoshop to analyze photographic images; data are shown as the area of the
contracted collagen lattice normalized to the average area of contraction seen in untreated cells, set as a baseline value of 1. Each data point represents
the mean ± SEM of the averages of triplicate reads for each culture derived from the four different patient samples both for CT- and DD-derived
fibroblasts. Statistical significance was determined using one-way ANOVA. *p < 0.05; **p< 0.01
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Meyer et al. [38] shows that increased circulating levels
of plasma TGFβ1 released from platelets contribute to
cardiac fibrosis that occurs in response to aortic con-
striction during cardiac surgery in humans. There is no
study to date that correlates the presence of TGF-β1 in
the palmar fascial tissues with elevated levels in circulat-
ing plasma in patients suffering from DD, but neither to
our knowledge has such a study been attempted. Inter-
estingly, a case study by Cutolo et al. [39] describes a
case of symmetric bilateral posterior subcapsular
cataracts associated with symmetric bilateral Dupuyt-
ren’s disease. In this study the authors found that the
patient’s serum TGF-β1 concentration was almost double
(18,290 pg/ml) compared to the cataract patients that
did not have Dupuytren’s disease (9961.06 pg/ml). Such
observations suggest that agents that will counteract
TGF-β1 may be useful adjuncts in the treatment of DD,
especially to guard against disease recurrence.
One such agent is Pirfenidone. Multiple in vitro and in
vivo studies have been performed to show the anti-
inflammatory and anti-fibrotic beneficial effects of PFD
on cell populations derived from various tissue sources
associated with fibrosis [29, 40–42]. Since PFD is already
FDA-approved for use in pulmonary fibrosis, there is a
substantial history of safety in human use. Our present





Fig. 5 Inhibition of α-SMA levels was evident after addition of Pirfenidone. CT- and DD-derived fibroblasts derived from three different patient samples
(N = 3/group) of were left untreated (Ntx) or were stimulated with PFD (800 μg/ml) in the presence or absence of TGF-β1 (10 ng/ml) in α-MEM
medium containing 0.1% dialyzed FBS. Twenty-four hours later cell lysates were collected to determine the mRNA and protein expression of α-SMA by
real-time RT-PCR (a & b) and Western blot analyses (c & d). Real-time RT-PCR experiments were done on three independent cultures of each of the cell
types. Values are mean ± SEM of three independent studies performed in triplicate. One-way ANOVA test was used to determine the statistical
significance. *p < 0.05, **p < 0.01. Western blot analyses shown here are representative images of experiments performed using three independent
primary cultures of CT- and DD-cord derived fibroblasts. Proteins obtained from different patients were processed in parallel to confirm the changes
that are observed are consistent. Protein accumulation was quantified by densitometry using GAPDH as a loading control (e)
Zhou et al. BMC Musculoskeletal Disorders  (2016) 17:469 Page 8 of 12
a b
c d
Fig. 6 Pirfenidone effectively inhibited TGF-β1-induction of α-2 chain of Type I and α-1 chain of Type III collagen. CT- and DD-derived fibroblasts derived
from three independent patient samples (N = 3/group) were left untreated (Ntx) or exposed to PFD (800 μg/ml) in the presence or absence of TGF-β1 for
24 h. Twenty-four hours later RNA was extracted and mRNA expression levels of type I and type III collagen of CT- (a & b) and DD-derived fibroblasts
(c & d) were determined using real-time RT-PCR analysis. Shown is the mean ± SEM of n= 3 of experimental replicates from three different culture of
CT- and DD-fibroblasts, each performed in triplicate. *p < 0.05, **p < 0.01
Fig. 7 Pirfenidone substantially reduced TGF-β1 induction of fibronectin expression. CT- and DD-cord derived fibroblasts grown in growth medium
overnight were treated with medium containing 0.1% dialyzed FBS for 24 h. Following which, cells were treated with 800 μg/mL of PFD with or
without 10 ng/ml TGF-β1 for 24 h. After the treatment, secreted proteins in the growth medium were collected to determine the fibronectin
expression using Human Fibronectin SimpleStep ELISA Kit. CT- and DD-derived fibroblasts derived from three different patient samples (N = 3/group)
were used to perform the experiment three times in triplicate. Statistical significance was determined by One-way ANOVA. *p < 0.05
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elicit similar anti-fibrotic effects against the altered
physiology of Dupuytren’s disease at the cellular level.
We find that PFD is able to inhibit cell proliferation,
migration (after TGF-β1 stimulation), and contraction of
DD fibroblasts, and also inhibits the expression of colla-
gen and fibronectin, two key components of the DD
ECM. A similar effect (sometimes not quite as pro-
nounced) is seen in CT fibroblasts, as may be expected
from an agent known to have broadly anti-fibrotic
effects in a variety of tissue and disease circumstances.
These observations indicate that PFD should be consid-
ered as a therapeutic agent against DD in a clinical trial.
Others have likewise suggested the use of other anti-
TGF-β1 medicaments such as N-acetyl-L-cysteine
(NAC) and ACE inhibitors as therapeutic interventions
for DD [43], but no such trial has, to our knowledge
been carried out.
TGF- β1 can signal via the Smad signaling pathways or
by the activation of non-Smad signaling pathways in-
cluding MAP kinase, Rho GTPase, and PI3 kinase-Akt,
resulting in repression of epithelial marker genes and
activation of mesenchymal markers [44, 45]. In order to
explore the mechanisms through which TGF- β1 actions
are inhibited by PFD we examined the Smad-dependent
pathways. Studies from other cell types indicate that
PFD counteracts TGF- β1 action by down-regulating
phosphorylation of Smad proteins [46–49]. A previous
study by Krause et al., [36] shows that DD tissues have
elevated basal expression of Smad2 and Smad3, and
P-Smad2 levels were found to be elevated, but not
P-Smad3 levels. In our DD- derived fibroblasts in culture
we did not find any such increase in the basal phosphor-
ylation of Smad2/Smad3 compared to CT cells, but posit
this may be due to the lack of stimulation by TGF- β1
(whereas DD tissues in vivo may be expected to see such
stimulation). When TGF-β1 was added to cells, we did
see significantly increased expression of P-Smad2 but
not P-Smad3 in DD- derived fibroblasts, consistent with
the observation in tissues. CT-derived fibroblasts also
showed this increase in culture, but would not be
expected to in vivo, where presumably there is little
TGF-β1 stimulation in CT disease. Importantly, in both
cell types the increase in P-Smad2 was negated by the
addition of PFD. This does suggest that, in both DD and
control palmar fascial fibroblasts. PFD is acting at least
partially through suppression of the canonical Smad
signaling pathway.
In sum, we show that PFD has significant physiologic
effects and anti-TGF-β1 properties in palmar fascial
fibroblasts as it does in cells from other tissue sources.
Importantly, PFD is effective against actively diseased




Fig. 8 Pirfenidone inhibits TGF-β1-induced phosphorylation of Smad2/Smad3. CT-and DD-cord-derived fibroblasts derived from three different patient
samples (N = 3/group) were maintained in MEM- α medium containing 0.1% dialyzed FBS for 24 h. After 24 h, cells were either treated or untreated
with PFD (800 μg/ml) in the presence or absence of TGF-β1 (10 ng/ml) for additional 24 h. Cell lysates collected from CT- (a & b) and DD- derived
fibroblasts were used to examine the expression of phosphorylated Smad2/Smad3 by Western blot analysis. Proteins obtained from different patients
were processed in parallel to confirm the changes that are observed are consistent. Densitometry results are reported as the ratio of
phosphorylated Smad2/Smad3 protein to GAPDH expression (c). Shown here is the representation of Western blot experiments performed
using three different culture each of CT- and DD-derived fibroblasts essentially with identical results. *p < 0.05
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expected to have a similar potency in vivo, potentially
mitigating DD disease and recurrence. It remains to be de-
termined how best to deliver PFD to the target cell popu-
lations in the setting of DD; to date its use has largely
been as a systemic (oral) medication, which may also
prove useful against DD. However, gel formulations of
PFD intended for topical administration have also been
described. A recent clinical trial by Armendariz-Borunda
et al. [27] shows that topical administration of 8% PFD
gels is effective and safe in the treatment of hypertrophic
scars caused by burns in children. Another recent study
by Rodríguez-Castellanos et al. [50] shows that topical ap-
plication of 8 % PFD gels to localized scleroderma reduces
both inflammation and fibrosis. These studies raise the
prospect of using PFD locally in DD patients rather than
via systemic oral administration. The main impediment to
such a scheme may be in delivering sufficient PFD to cross
the skin barrier to underlying palmar fascial tissue. How-
ever, we anticipate that doses used in this study will be
achievable in vivo. Since we are aiming for topical applica-
tion of PFD for use in DD patients, we expect that we can
achieve the effect of the drug locoregionally with much
less systemic exposure than used for treating other fibrotic
conditions such as idiopathic pulmonary fibrosis (IPF).
Future studies will focus on optimizing strategies to effect-
ively deliver PFD to the palmar fascia, and to verify its
ability to inhibit DD disease phenotype using a recently
described orthotopic animal model of DD [31].
Conclusions
Taken together these results suggest the PFD can poten-
tially prevent TGF-β1-induced fibroblast to myofibroblast
transformation and inhibit ECM production mainly Type
I- and Type III- collagen and fibronectin in DD-derived
fibroblasts. Further in-vivo studies with PFD may lead to a
novel therapeutic application in preventing the progres-
sion or recurrence of Dupuytren’s disease.
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